Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Respiratory Syncytial Virus (RSV) is a significant cause of lower respiratory tract infections in the young, the elderly, and in immunodeficient patients. As such, the virus represents an important cause of morbidity and mortality worldwide. Development of monoclonal antibodies against RSV has resulted in a commercial prophylaxis, palivizumab (Synagis), and different antibodies that have improved our understanding of the structure of the viral proteins. In this study, a different immunization technique, subtractive immunization, was evaluated for its applicability to develop RSV-specific antibodies. One hybridoma which produced antibodies with the strongest staining of RSV infected cells, ATAC-0025, was selected for further characterization. This antibody belongs to the IgG1 class, has neutralizing capacity and recognizes the envelope F-protein. The antibody has a broad reactivity against a range of RSV reference strains and clinical isolates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594476 | PMC |
| http://dx.doi.org/10.3390/antib12040062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Computational identification of membrane proteins for vaccine design against drug-resistant Moraxella catarrhalis.
Mol Genet Genomics
September 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, Multan, 66000, Punjab, Pakistan.
Moraxella catarrhalis is a Gram-negative diplococcus bacterium and a common respiratory pathogen, implicated in 15-20% of otitis media (OM) cases in children and chronic obstructive pulmonary disease (COPD) in adults. The rise of drug-resistant Moraxella catarrhalis has highlighted the urgent need for the potent vaccine strategies to reduce its clinical burden. Despite a mortality rate of 13%, there is no FDA-approved vaccine for this pathogen.
View Article and Find Full Text PDFRational design of a multi epitope vaccine against Salmonella typhi via subtractive proteomics, reverse vaccinology and molecular modeling.
Sci Rep
September 2025
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Salmonella enterica subsp. enterica serotype Typhi (Salmonella typhi) is the cause of typhoid fever, a severe public health issue in impoverished countries with inadequate sanitation. Despite the availability of therapies, infection rates remain high, underscoring the critical need for an effective and long-lasting vaccine.
View Article and Find Full Text PDFTargeting Streptococcus pyogenes atpF protein for multi-epitope vaccine development: a genomics-driven immunoinformatics strategy.
J Genet Eng Biotechnol
September 2025
Department of Chemistry, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. Electronic address:
Streptococcus pyogenes, a medium-priority pathogen on the WHO's 2024 Bacterial Pathogen Priority List, is a major cause of infectious disease-related mortality. The increasing prevalence of antibiotic resistance, coupled with the absence of a licensed vaccine due to the pathogen's genetic diversity and autoimmune concerns, underscores the need for novel therapeutic strategies. This study employs reverse vaccinology and subtractive proteomics to design a multi-epitope vaccine targeting atpF, a conserved extracellular protein essential for ATP synthesis.
View Article and Find Full Text PDFScreening of novel therapeutic targets and chimeric vaccine construction against antibiotic-resistant .
Front Immunol
August 2025
Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
is known to cause a variety of infections, including mild gastroenteritis and severe systemic disease. This bacterium has developed resistance to several antibiotics, including cephalosporins, penicillins, and fluoroquinolones. Despite significant advances in vaccine formulation against , there is no FDA-licensed vaccine available against it.
View Article and Find Full Text PDFAdditions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy.
Crit Rev Oncol Hematol
July 2025
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, No. 440 Jiyan Road, Jinan, Shandong 250117, China. Electronic address:
Oligometastatic non-small cell lung cancer (NSCLC) is a distinct subtype characterized by a limited number of metastatic lesions. Radiotherapy (RT) is vital in treating NSCLC. However, the role of RT should be investigated further as the treatment of NSCLC has been revolutionized by immunotherapy.
View Article and Find Full Text PDF